Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Shareholder Meeting (May 2025)
33 slides from Imricor Medical Systems's shareholder meeting presentation, May 2025
Slide 1: Annual General Meeting May 2025
rsonal use only Annual General Meeting May 2025 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer The material contained in this presentation is intended to be general background those which we expect, depending on the outcome of various factors. Investors and others information on Imricor Medical Systems, Inc. (Imricor) and its activities. are cautioned not to place undue reliance on
Slide 3: Please submit questions at any time throughout the meeting
Please submit questions at any time throughout the meeting To ask a question select the ‘Q&A’ icon rsonal use only Select the topic your question relates to. Type your question into the chat box at the bottom of the screen and press ‘Send’ Your question will be sent immediately for review 2025 AGM |
Slide 4: Voting online at the virtual meeting
Voting online at the virtual meeting When the Chair declares the poll open, select the ‘Vote’ icon and the rsonal use only voting options will appear on your screen To vote, select your voting direction. A tick will appear to confirm receipt of your vote To change your vote, select ‘Click here to ch
Slide 5: Imricor's Board of Directors and CFO
Imricor’s Board of Directors and CFO rsonal use only Steve Wedan Mark Tibbles Anita Messal Peter McGregor Jeffrey Leighton Jonathon Gut Executive Chair, Deputy Chair, Non-Executive Director Non-Executive Director Non-Executive Director CFO President, & CEO Non-Executive Director 2025 AGM | 5
Slide 6: Chair's Address
rsonal use only Chair’s Address
Slide 7: Dr. Marco Götte testimonial on NorthStar in the iCMR
rsonal use only "What may have taken several hours in the x-ray lab took less than an hour to perform using NorthStar in the iCMR." Dr. Marco Götte - Amsterdam UMC, April 2024
Slide 8: Building success: accomplishments in 2024 and up to today
Building success rsonal use only Accomplishments in 2024 and up to today • Expanded commercially into the Middle East • Completed transition to EU’s more stringent Medical Device Regulations • Activated sites and building pipeline of new sites • Commenced VISABL-AFL (supporting US FDA) • Progressed
Slide 9: Imricor Leadership Team
Imricor Leadership Team Management Board of Directors rsonal use only Steve Wedan Jonathon Gut Gregg Stenzel Jennifer Weisz Nick Twohy President and Chief Vice President of Vice President Executive Officer, Finance and Chief Chief Operating Vice President Marketing & Mark Tibbles Peter McGregor Stev
Slide 10: Business of the Meeting
rsonal use only Business of the Meeting
Slide 11: Questions
rsonal use only Questions
Slide 12: Election of Class III Director – Mr Peter McGregor
Item 1 – Election of Class III Director – Mr Peter McGregor rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That Mr Peter McGregor being a Director whose appointment as a Director expires at the conclusion of the Annual Meeting of
Slide 13: Election of Class III Director – Mr Peter McGregor: votes
Item 1 – Election of Class III Director – Mr Peter McGregor rsonal use only Proxy and direct votes received in respect of this resolution: For Withheld Non-Votes Uncast 103,699,623 1,370,217 - - 98.70% 1.30% 2025 AGM | 13
Slide 14: Election of Class III Director – Dr Jeffrey Leighton
Item 2 – Election of Class III Director – Dr Jeffrey Leighton rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That Dr Jeffrey Leighton being a Director whose appointment as a Director expires at the conclusion of the Annual Meetin
Slide 15: Election of Class III Director – Dr Jeffrey Leighton: votes
Item 2 – Election of Class III Director – Dr Jeffrey Leighton rsonal use only Proxy and direct votes received in respect of this resolution: For Withheld Non-Votes Uncast 105,069,840 - - - 100% - 2025 AGM | 15
Slide 16: Approval of the 2019 Equity Incentive Plan and increase in reserved Shares
Item 3 – Approval of the 2019 Equity Incentive Plan and increase in reserved Shares rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That, for the purposes of section 19.2 of the Plan (defined below), Exception 13 of ASX Listing Ru
Slide 17: Equity Incentive Plan: votes
Item 3 – Approval of the 2019 Equity Incentive Plan and increase in reserved Shares rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 93,054,094 5,214,130 95,728 - 6,705,888 94.60% 5.30% 0.10% 2025 AGM | 17
Slide 18: 4a – Grant of Options to Mr Steve Wedan
Item 4a – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company rsonal use only To consider and, if thought fit, to pass the following resolutions as separate ordinary resolutions: (a) “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is give
Slide 19: 4a – Grant of Options to Mr Steve Wedan: votes
Item 4a – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 93,081,694 5,281,658 600 - 6,705,888 94.63% 5.37% - 2025 AGM | 19
Slide 20: 4b – Grant of Options to Mr Steve Wedan
Item 4b – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company rsonal use only To consider and, if thought fit, to pass the following resolutions as separate ordinary resolutions: (b) “That, subject to Item 3 being approved, for the purposes of ASX Listing Rule 10.14 and for al
Slide 21: 4b – Grant of Options to Mr Steve Wedan: votes
Item 4b – Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 71,570,518 26,732,834 60,600 - 6,705,888 72.76% 27.18% 0.06% 2025 AGM | 21
Slide 22: Grant of Restricted Stock Award to Mr Peter McGregor
Item 5 – Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That, subject to Item 1 being approved, for the purposes of ASX Listing Rule 10.1
Slide 23: Restricted Stock Award to Mr Peter McGregor: votes
Item 5 – Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 93,142,835 5,220,517 433,455 - 6,273,033 94.28% 5.28% 0.44% 2025 AGM | 23
Slide 24: Grant of Restricted Stock Award to Ms Anita Messal
Item 6 – Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approv
Slide 25: Restricted Stock Award to Ms Anita Messal: votes
Item 6 – Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 93,142,835 5,220,517 600 - 6,705,888 94.69% 5.31% - 2025 AGM | 25
Slide 26: Grant of Restricted Stock Award to Mr Mark Tibbles
Item 7 – Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approv
Slide 27: Restricted Stock Award to Mr Mark Tibbles: votes
Item 7 – Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 93,088,694 5,274,658 600 - 6,705,888 94.64% 5.36% - 2025 AGM | 27
Slide 28: Ratification and approval of prior issue of CDIs under Placement
Item 8 – Ratification and approval of prior issue of CDIs under Placement rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the stockholders ratify and appro
Slide 29: Ratification of CDI Placement: votes
Item 8 – Ratification and approval of prior issue of CDIs under Placement rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 82,317,014 78,772 11,212,411 - 11,461,643 87.94% 0.08% 11.98% 2025 AGM | 29
Slide 30: Ratification of appointment of BDO USA, P.C.
Item 9 – Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm rsonal use only To consider and, if thought fit, to pass the following resolution as a separate ordinary resolution: “That the stockholders ratify and approve the appointment of BDO USA, P.C. a
Slide 31: Ratification of BDO USA, P.C. appointment: votes
Item 9 – Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm rsonal use only Proxy and direct votes received in respect of this resolution: For Against Abstain Non-Votes Uncast 105,057,128 4,581 8,131 - - 99.99% - 0.01% 2025 AGM | 31
Slide 32: Close of Meeting
rsonal use only Close of Meeting
Slide 33: Contact Information
Contact Information rsonal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Nick.corkill@imricor.com +
Imricor Medical Systems — Shareholder Meeting (May 2025) on 6ix